celecoxib has been researched along with Chemotherapy-Induced Acral Erythema in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hand-foot syndrome (HFS) is a common cutaneous side effect of capecitabine therapy." | 9.51 | Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study). ( Batra, A; Cheung, WY; Gogia, A; Gupta, I; Gupta, N; Kumar, A; Pandey, RM; Pramanik, R; Prasad, CP; Santhosh, A; Sharma, A, 2022) |
| "Capecitabine-induced hand-foot syndrome (HFS) is common in clinical practice." | 9.22 | Pharmacological prevention strategy for capecitabine-induced hand-foot syndrome: A network meta-analysis of randomized control trials. ( Hung, CH; Kao, YS; Lo, CH; Tu, YK, 2022) |
| " From August 2008 to December 2010, stage II and III colorectal cancer patients receiving capecitabine-based chemotherapy enrolled in the trial voluntarily." | 9.16 | Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. ( Chen, G; Kong, LH; Lu, ZH; Pan, ZZ; Wan, DS; Wu, XJ; Zhang, RX, 2012) |
| "Oral celecoxib has been proved to be the best pharmacological intervention to ameliorate the skin lesions." | 7.30 | Pharmaceutical and clinical studies of celecoxib topical hydrogel for management of chemotherapy-induced hand-foot syndrome. ( Afshar, M; Gharib, B; Jafariazar, Z; Ramezannia, F; Rezaeilaal, A; Shahi, F; Shayeganmehr, D, 2023) |
| "Hand-foot syndrome (HFS) is a common cutaneous side effect of capecitabine therapy." | 5.51 | Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study). ( Batra, A; Cheung, WY; Gogia, A; Gupta, I; Gupta, N; Kumar, A; Pandey, RM; Pramanik, R; Prasad, CP; Santhosh, A; Sharma, A, 2022) |
| "Capecitabine-induced hand-foot syndrome (HFS) is common in clinical practice." | 5.22 | Pharmacological prevention strategy for capecitabine-induced hand-foot syndrome: A network meta-analysis of randomized control trials. ( Hung, CH; Kao, YS; Lo, CH; Tu, YK, 2022) |
| " From August 2008 to December 2010, stage II and III colorectal cancer patients receiving capecitabine-based chemotherapy enrolled in the trial voluntarily." | 5.16 | Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. ( Chen, G; Kong, LH; Lu, ZH; Pan, ZZ; Wan, DS; Wu, XJ; Zhang, RX, 2012) |
| "Oral celecoxib has been proved to be the best pharmacological intervention to ameliorate the skin lesions." | 3.30 | Pharmaceutical and clinical studies of celecoxib topical hydrogel for management of chemotherapy-induced hand-foot syndrome. ( Afshar, M; Gharib, B; Jafariazar, Z; Ramezannia, F; Rezaeilaal, A; Shahi, F; Shayeganmehr, D, 2023) |
| "Celecoxib was effective in preventing HFS in patients who received capecitabine (50." | 2.82 | Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials. ( Franco, PIG; Li, RK; Pandy, JGP, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 4 (80.00) | 2.80 |
| Authors | Studies |
|---|---|
| Santhosh, A | 1 |
| Kumar, A | 1 |
| Pramanik, R | 1 |
| Gogia, A | 1 |
| Prasad, CP | 1 |
| Gupta, I | 1 |
| Gupta, N | 1 |
| Cheung, WY | 1 |
| Pandey, RM | 1 |
| Sharma, A | 1 |
| Batra, A | 1 |
| Pandy, JGP | 1 |
| Franco, PIG | 1 |
| Li, RK | 1 |
| Kao, YS | 1 |
| Lo, CH | 1 |
| Tu, YK | 1 |
| Hung, CH | 1 |
| Shayeganmehr, D | 3 |
| Ramezannia, F | 3 |
| Gharib, B | 3 |
| Rezaeilaal, A | 3 |
| Shahi, F | 3 |
| Jafariazar, Z | 3 |
| Afshar, M | 3 |
| Zhang, RX | 1 |
| Wu, XJ | 1 |
| Wan, DS | 1 |
| Lu, ZH | 1 |
| Kong, LH | 1 |
| Pan, ZZ | 1 |
| Chen, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine: A Randomized Controlled Trial.[NCT05641246] | Phase 2 | 66 participants (Anticipated) | Interventional | 2022-12-08 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for celecoxib and Chemotherapy-Induced Acral Erythema
| Article | Year |
|---|---|
Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.
Topics: Capecitabine; Celecoxib; Hand-Foot Syndrome; Humans; Neoplasms; Pyridoxine; Randomized Controlled Tr | 2022 |
Pharmacological prevention strategy for capecitabine-induced hand-foot syndrome: A network meta-analysis of randomized control trials.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Celecoxib; Hand-Foot Syndrome; Humans; Network Meta-A | 2022 |
3 trials available for celecoxib and Chemotherapy-Induced Acral Erythema
| Article | Year |
|---|---|
Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study).
Topics: Antimetabolites, Antineoplastic; Capecitabine; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; H | 2022 |
Pharmaceutical and clinical studies of celecoxib topical hydrogel for management of chemotherapy-induced hand-foot syndrome.
Topics: Animals; Antineoplastic Agents; Celecoxib; Hand-Foot Syndrome; Humans; Hydrogels; Rats; Rats, Wistar | 2023 |
Pharmaceutical and clinical studies of celecoxib topical hydrogel for management of chemotherapy-induced hand-foot syndrome.
Topics: Animals; Antineoplastic Agents; Celecoxib; Hand-Foot Syndrome; Humans; Hydrogels; Rats; Rats, Wistar | 2023 |
Pharmaceutical and clinical studies of celecoxib topical hydrogel for management of chemotherapy-induced hand-foot syndrome.
Topics: Animals; Antineoplastic Agents; Celecoxib; Hand-Foot Syndrome; Humans; Hydrogels; Rats; Rats, Wistar | 2023 |
Pharmaceutical and clinical studies of celecoxib topical hydrogel for management of chemotherapy-induced hand-foot syndrome.
Topics: Animals; Antineoplastic Agents; Celecoxib; Hand-Foot Syndrome; Humans; Hydrogels; Rats; Rats, Wistar | 2023 |
Pharmaceutical and clinical studies of celecoxib topical hydrogel for management of chemotherapy-induced hand-foot syndrome.
Topics: Animals; Antineoplastic Agents; Celecoxib; Hand-Foot Syndrome; Humans; Hydrogels; Rats; Rats, Wistar | 2023 |
Pharmaceutical and clinical studies of celecoxib topical hydrogel for management of chemotherapy-induced hand-foot syndrome.
Topics: Animals; Antineoplastic Agents; Celecoxib; Hand-Foot Syndrome; Humans; Hydrogels; Rats; Rats, Wistar | 2023 |
Pharmaceutical and clinical studies of celecoxib topical hydrogel for management of chemotherapy-induced hand-foot syndrome.
Topics: Animals; Antineoplastic Agents; Celecoxib; Hand-Foot Syndrome; Humans; Hydrogels; Rats; Rats, Wistar | 2023 |
Pharmaceutical and clinical studies of celecoxib topical hydrogel for management of chemotherapy-induced hand-foot syndrome.
Topics: Animals; Antineoplastic Agents; Celecoxib; Hand-Foot Syndrome; Humans; Hydrogels; Rats; Rats, Wistar | 2023 |
Pharmaceutical and clinical studies of celecoxib topical hydrogel for management of chemotherapy-induced hand-foot syndrome.
Topics: Animals; Antineoplastic Agents; Celecoxib; Hand-Foot Syndrome; Humans; Hydrogels; Rats; Rats, Wistar | 2023 |
Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial.
Topics: Adenocarcinoma; Aged; Algorithms; Antimetabolites, Antineoplastic; Capecitabine; Celecoxib; Colorect | 2012 |